Drugs / NANOS1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05822180 | Jan 2021 → Jan 2022 | pneumonia | General Administration of Military Health, Tunisia | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NANOS1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05822180 ↗ |
| Known as | argent colloïdal | “Drug: NANOS1 , argent colloïdal ,” NCT05822180 ↗ |
| Route | Oral | “The experimental arm has received the Nanos product orally” NCT05822180 ↗ |